Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
| Revenue (TTM) | $45.13B |
| Gross Profit (TTM) | $25.50B |
| EBITDA | $11.74B |
| Operating Margin | 13.50% |
| Return on Equity | 12.30% |
| Return on Assets | 5.59% |
| Revenue/Share (TTM) | $25.91 |
| Book Value | $29.89 |
| Price-to-Book | 3.19 |
| Price-to-Sales (TTM) | 3.67 |
| EV/Revenue | 4.274 |
| EV/EBITDA | 16.30 |
| Quarterly Earnings Growth (YoY) | -19.70% |
| Quarterly Revenue Growth (YoY) | 7.80% |
| Shares Outstanding | $1.74B |
| Float | $1.73B |
| % Insiders | 0.49% |
| % Institutions | 82.53% |
Volatility is currently expanding
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Abbott Laboratories is upgraded to Buy ahead of Q2 2026 earnings, following a challenging period marked by share price underperformance. The recent acquisition of Exact Sciences adds a high-growth cancer diagnostics vertical, targeting $3bn incremental 2026 sales and potential long-term revenue expansion. 2026 guidance projects 6.5–7.5% organic sales growth and $5.38–$5.58 adjusted EPS, with Exact Sciences acquisition causing $0.20 EPS dilution.
Passive income is characterized by its ability to generate revenue without requiring the earner's continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence.
Futures are trading lower as we get ready to start the third quarter after a record-setting second quarter that saw the Dow Jones Industrial Average close at 52,317, up 0.26% to finish the venerable index's best first half since 2021, while the Nasdaq finished the session at 26,213, up 1.52% for the tech-heavy index's best quarterly finish since 2020.
The latest trading day saw Abbott (ABT) settling at $92.71, representing a -1.5% change from its previous close.
This relationship between inflation and value stocks' outperformance is often overlooked. Many investment experts mistakenly believe that a strong economy, not inflation, is the key to value stocks beating growth stocks.
ABT's Medical Devices unit builds on strong growth with new diabetes, heart rhythm and electrophysiology advances ahead of Q2 2026.
The U.S. Justice Department closed a criminal probe into Abbott Laboratories over how it managed a baby formula facility where potentially deadly bacteria were discovered and suspected of causing infant deaths, and instead opted for civil penalties, the Wall Street Journal reported on Sunday, citing people familiar with the matter.
WASHINGTON—The Justice Department spent years investigating Abbott Laboratories ABT 0.94%increase; up pointing triangle over how it managed a baby formula facility where potentially deadly bacteria was discovered and suspected of causing infant deaths, worsening a national shortage.
